JPS5042087A - - Google Patents

Info

Publication number
JPS5042087A
JPS5042087A JP49083733A JP8373374A JPS5042087A JP S5042087 A JPS5042087 A JP S5042087A JP 49083733 A JP49083733 A JP 49083733A JP 8373374 A JP8373374 A JP 8373374A JP S5042087 A JPS5042087 A JP S5042087A
Authority
JP
Japan
Prior art keywords
biocatalyst
polyalkyl
polyalkoxy
polyalkoxy polymer
unsubstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP49083733A
Other languages
Japanese (ja)
Other versions
JPS5623587B2 (en
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of JPS5042087A publication Critical patent/JPS5042087A/ja
Publication of JPS5623587B2 publication Critical patent/JPS5623587B2/ja
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
    • C12N11/08—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer
    • C12N11/089—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4826—Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Polymers & Plastics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Peptides Or Proteins (AREA)

Abstract

A method for suppressing the immunogenic action of a biocatalyst which has a large number of peptide linkages, with at least partial retention of its physiological activity, entails attaching polymers to the biocatalyst; the biocatalyst is attached to a virtually linear polyalkyl or polyalkoxy polymer via at least one terminal carbon atom thereof; the polyalkyl or polyalkoxy polymer is unsubstituted or substituted by an alkoxy or alkyl group containing fewer than 5 C atoms.
JP8373374A 1973-07-20 1974-07-20 Expired JPS5623587B2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38119173A 1973-07-20 1973-07-20

Publications (2)

Publication Number Publication Date
JPS5042087A true JPS5042087A (en) 1975-04-16
JPS5623587B2 JPS5623587B2 (en) 1981-06-01

Family

ID=23504063

Family Applications (1)

Application Number Title Priority Date Filing Date
JP8373374A Expired JPS5623587B2 (en) 1973-07-20 1974-07-20

Country Status (9)

Country Link
JP (1) JPS5623587B2 (en)
CA (1) CA1033673A (en)
CH (1) CH616942A5 (en)
DE (1) DE2433883C2 (en)
FR (1) FR2313939A1 (en)
GB (1) GB1469472A (en)
IL (1) IL45291A0 (en)
NL (1) NL7409770A (en)
SE (1) SE441753B (en)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59204130A (en) * 1983-04-30 1984-11-19 Nippon Chemiphar Co Ltd Oral administration drug containing novel plasminogen activator derivative
JPS6094999A (en) * 1983-09-23 1985-05-28 ヘキスト・アクチエンゲゼルシヤフト Insulin derivatives and their production method
WO1985003934A1 (en) * 1984-03-06 1985-09-12 Takeda Chemical Industries, Ltd. Chemically modified protein and process for its preparation
JP2003508498A (en) * 1999-09-10 2003-03-04 ザ、プロクター、エンド、ギャンブル、カンパニー Enzyme inhibitor
JP2005506351A (en) * 2001-10-18 2005-03-03 ネクター セラピューティックス エイエル，コーポレイション Polymer conjugate opioid antagonist
JP2005528372A (en) * 2002-03-26 2005-09-22 バイオシネクサス インコーポレイテッド Antibacterial polymer composite
JP2006510396A (en) * 2002-10-21 2006-03-30 アルヴィヴォ インコーポレイテッド Surface coating containing bioactive compounds
JP2006510601A (en) * 2002-09-30 2006-03-30 マウンテン ビュー ファーマシューティカルズ，インコーポレイテッド Polymer conjugate with reduced antigenicity, method of preparation and use thereof
JP2009507943A (en) * 2005-08-26 2009-02-26 エンゾン ファーマスーティカルズ インコーポレイテッド Process for preparing polymers having terminal amine groups
JP2016037503A (en) * 2001-10-10 2016-03-22 ノボ ノルデイスク エイ エス Peptide remodeling and glycoconjugation
JP2017536387A (en) * 2014-12-02 2017-12-07 アントリアバイオ インコーポレイテッドＡｎｔｒｉａｂｉｏ，Ｉｎｃ． Proteins and protein conjugates with increased hydrophobicity
JP2019521179A (en) * 2016-06-01 2019-07-25 セルヴィエ アイピー ユーケー リミテッド Preparation of polyalkylene oxide-asparaginase and process for its preparation and use
JP2019527246A (en) * 2016-05-31 2019-09-26 ローベルト ボツシユ ゲゼルシヤフト ミツト ベシユレンクテル ハフツングＲｏｂｅｒｔ Ｂｏｓｃｈ Ｇｍｂｈ Azlactone-functionalized substrates for conjugating biomolecules

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2930542A1 (en) * 1979-07-27 1981-02-12 Hoechst Ag NEW INSULINE DERIVATIVES AND METHOD FOR THEIR PRODUCTION
JPS61163687U (en) * 1985-03-28 1986-10-09
JPS62207485A (en) * 1986-03-07 1987-09-11 大平技研工業株式会社 Television game machine
US5037969A (en) * 1986-07-03 1991-08-06 Takeda Chemical Industries, Ltd. Glycosyl derivatives and use thereof
US5166322A (en) * 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
WO1993012145A1 (en) * 1991-12-19 1993-06-24 Baylor College Of Medicine Pva or peg conjugates of peptides for epitope-specific immunosuppression
US5578496A (en) * 1991-12-19 1996-11-26 Board Of Regents, Baylor College Of Medicine Detection of autoantibodies associated with the disease myasthenia gravis
US5618528A (en) * 1994-02-28 1997-04-08 Sterling Winthrop Inc. Biologically compatible linear block copolymers of polyalkylene oxide and peptide units
US6323311B1 (en) 1999-09-22 2001-11-27 University Of Utah Research Foundation Synthesis of insulin derivatives
ATE492562T1 (en) 2003-09-24 2011-01-15 Kyowa Hakko Kirin Co Ltd RECOMBINANT ANTIBODY AGAINST HUMAN INSULIN-LIKE GROWTH FACTOR
US7790835B2 (en) 2003-12-03 2010-09-07 Nektar Therapeutics Method of preparing maleimide functionalized polymers
WO2006135930A2 (en) * 2005-06-13 2006-12-21 Nastech Pharmaceutical Company Inc. Transmucosal delivery of peptide derivatives

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3645852A (en) * 1967-05-23 1972-02-29 Pharmacia Ab Method of binding water-soluble proteins and water-soluble peptides to water-insoluble polymers using cyanogen halide

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3619371A (en) * 1967-07-03 1971-11-09 Nat Res Dev Production of a polymeric matrix having a biologically active substance bound thereto
US3674767A (en) * 1967-07-14 1972-07-04 Nat Res Dev Novel polymeric materials containing triazinyl groups

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3645852A (en) * 1967-05-23 1972-02-29 Pharmacia Ab Method of binding water-soluble proteins and water-soluble peptides to water-insoluble polymers using cyanogen halide

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59204130A (en) * 1983-04-30 1984-11-19 Nippon Chemiphar Co Ltd Oral administration drug containing novel plasminogen activator derivative
JPS6094999A (en) * 1983-09-23 1985-05-28 ヘキスト・アクチエンゲゼルシヤフト Insulin derivatives and their production method
WO1985003934A1 (en) * 1984-03-06 1985-09-12 Takeda Chemical Industries, Ltd. Chemically modified protein and process for its preparation
JP5020451B2 (en) * 1999-09-10 2012-09-05 ザ プロクター アンド ギャンブル カンパニー Enzyme inhibitor
JP2003508498A (en) * 1999-09-10 2003-03-04 ザ、プロクター、エンド、ギャンブル、カンパニー Enzyme inhibitor
JP2016037503A (en) * 2001-10-10 2016-03-22 ノボ ノルデイスク エイ エス Peptide remodeling and glycoconjugation
JP2005506351A (en) * 2001-10-18 2005-03-03 ネクター セラピューティックス エイエル，コーポレイション Polymer conjugate opioid antagonist
JP2009167214A (en) * 2001-10-18 2009-07-30 Nektar Therapeutics Al Corp Polymer conjugates of opioid antagonists
JP4814488B2 (en) * 2001-10-18 2011-11-16 ネクター セラピューティックス Polymer conjugate opioid antagonist
JP2005528372A (en) * 2002-03-26 2005-09-22 バイオシネクサス インコーポレイテッド Antibacterial polymer composite
JP2006510601A (en) * 2002-09-30 2006-03-30 マウンテン ビュー ファーマシューティカルズ，インコーポレイテッド Polymer conjugate with reduced antigenicity, method of preparation and use thereof
JP2011157379A (en) * 2002-09-30 2011-08-18 Mountain View Pharmaceuticals Inc Polymer conjugate with decreased antigenicity, method of preparation and use thereof
JP2006510396A (en) * 2002-10-21 2006-03-30 アルヴィヴォ インコーポレイテッド Surface coating containing bioactive compounds
JP2009507943A (en) * 2005-08-26 2009-02-26 エンゾン ファーマスーティカルズ インコーポレイテッド Process for preparing polymers having terminal amine groups
JP2017536387A (en) * 2014-12-02 2017-12-07 アントリアバイオ インコーポレイテッドＡｎｔｒｉａｂｉｏ，Ｉｎｃ． Proteins and protein conjugates with increased hydrophobicity
JP2019527246A (en) * 2016-05-31 2019-09-26 ローベルト ボツシユ ゲゼルシヤフト ミツト ベシユレンクテル ハフツングＲｏｂｅｒｔ Ｂｏｓｃｈ Ｇｍｂｈ Azlactone-functionalized substrates for conjugating biomolecules
JP2019521179A (en) * 2016-06-01 2019-07-25 セルヴィエ アイピー ユーケー リミテッド Preparation of polyalkylene oxide-asparaginase and process for its preparation and use

Also Published As

Publication number Publication date
DE2433883C2 (en) 1986-03-27
GB1469472A (en) 1977-04-06
SE441753B (en) 1985-11-04
DE2433883A1 (en) 1976-02-05
CH616942A5 (en) 1980-04-30
SE7409366L (en) 1975-01-21
CA1033673A (en) 1978-06-27
FR2313939B1 (en) 1979-05-18
IL45291A0 (en) 1974-10-22
JPS5623587B2 (en) 1981-06-01
NL7409770A (en) 1975-01-22
FR2313939A1 (en) 1977-01-07

Similar Documents

Publication Publication Date Title
FR2313939B1 (en)
ES8103171A1 (en) A MONACOLINE K PREPARATION PROCEDURE.
JPS546096A (en) Preparation of silyl-terminated polymer
ES462425A1 (en) Method of preparing novel bitumen compositions
ES440560A1 (en) PROCEDURE FOR THE PRODUCTION OF NEW RIFAMYCINS.
ES426303A1 (en) Procedure for the obtaining of oxazolidine derivatives. (Machine-translation by Google Translate, not legally binding)
SE7412347L (en)
ES441678A1 (en) Polymerizates of olefinic nitriles
BE848604A (en) TETRAKIS-ALKYL-PIPERIDONE-4 SUBSTITUTED OXIMES FOR USE AS ORGANIC STABILIZERS,
SU480711A1 (en) The method of obtaining derivatives of 3-hydroxymethylthiazoline-2,4
GB1328706A (en) 2,6-dialkyl-3-hydroxy-6-beta-carboxyethyl-caclohex-2-en-1-ones
ES427869A1 (en) 5-phenyl-sulphinyl-2-benzimidazolyl-carbamic acid esters and process for their manufacture
ES390952A1 (en) Procedure for the preparation of 2-piperidilcarbinols. (Machine-translation by Google Translate, not legally binding)
ES429691A1 (en) Preparation of p-isobutyl hydratropic acid and intermediates therefor
DE3267690D1 (en) Process for the preparation of 3-alkyl-6-methyl-beta-resorcylic-acid esters
GB1315670A (en) Pyrolysis of nickel salts of phosphonic acid monoesters
ES457416A1 (en) A procedure for the preparation of poly (tetrametileneter) glicol. (Machine-translation by Google Translate, not legally binding)
ES394637A1 (en) Vinyl esters polymers containing hindered phenolic groups
ES442022A1 (en) Phenylpropanolamines
GB1480045A (en) Hindered phenol derivatives of 9-thiabicyclononanes and stabilised compositions
SU593451A1 (en) METHOD FOR STABILIZATION
JPS5416466A (en) Novel 3-hydroxypyrrolldine-3-carboxylic derivative
JPS51136784A (en) Method f or preparing a polymer containing a a skelton of stabilizer in the molecule
ES427622A1 (en) Procedure for the preparation of 2-amino-bencil-amines. (Machine-translation by Google Translate, not legally binding)
ES403328A1 (en) Novel bicycloalkane derivatives